Vinh Nguyen, MD
Cardiovascular Disease · Temple, TXNPI 1881940369
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $54,357 of the $64,497 with a category attached, or 84.3%. E.r. Squibb & Sons, L.L.C. accounts for 95.6% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $32,220 and has fallen 98.7% since, to $416 in 2025. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 140 payments — averaging $460.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$62K
- Bristol Myers Squibb$600
- AstraZeneca$392
- Atricure, Inc.$353
- Pfizer$302
- Amgen$198
- plus $1K from 14 others
Across 3 payments — averaging $36,225 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$109K
What the payments were for
- Consulting fees$1,2002%
- Speaking & faculty fees$54,35784%
- Travel & lodging$4,3497%
- Food & beverage$4,4917%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 86 | $61,648 |
| Bristol Myers Squibb | 2 | $600 |
| AstraZeneca | 5 | $392 |
| Atricure, Inc. | 2 | $353 |
| Pfizer | 10 | $302 |
| Amgen | 6 | $198 |
| Boston Scientific | 3 | $163 |
| Lantheus Medical Imaging, Inc. | 6 | $157 |
| Johnson & Johnson | 7 | $133 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $117 |
| Alnylam Pharmaceuticals Inc. | 2 | $59 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Novartis | 1 | $22 |
| Agepha Pharma FZ LLC | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Bracco Diagnostics Inc. | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$29,402
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$353
- Watchman$134
- LIBTAYO$125
- Repatha$125
- DISEASE STATE$125
- ELIQUIS$120
How this compares
$64,497 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CamzyosMavacamten | 135 | $1,115,732 |
| EntrestoSacubitril/Valsartan | 18 | $31,471 |
| JardianceEmpagliflozin | 13 | $21,900 |
| EliquisApixaban | 13 | $11,764 |
| Disopyramide Phosphate | 14 | $5,237 |
| Atorvastatin Calcium | 68 | $1,413 |
| Ranolazine ErRanolazine | 11 | $1,155 |
| Carvedilol | 39 | $736 |
| Metoprolol Succinate | 35 | $700 |
| Ezetimibe | 20 | $648 |
| Losartan Potassium | 28 | $561 |
| Nifedipine ErNifedipine | 15 | $472 |
| Rosuvastatin Calcium | 17 | $344 |
| Metoprolol Tartrate | 30 | $295 |
| Spironolactone | 24 | $184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $61,648 | $1,115,732135 claims |
| NovartisEntresto | $22 | $31,47118 claims |
| Boehringer IngelheimJardiance | $17 | $21,90013 claims |
| PfizerEliquis | $302 | $11,76413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Temple
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
- Reynolds DelgadoHouston$471K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.